Last A$0.08 AUD
Change Today -0.001 / -1.32%
Volume 271.6K
As of 12:20 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd (QRX) Snapshot

Open
A$0.08
Previous Close
A$0.08
Day High
A$0.08
Day Low
A$0.08
52 Week High
08/14/13 - A$1.25
52 Week Low
05/8/14 - A$0.07
Market Cap
12.3M
Average Volume 10 Days
289.4K
EPS TTM
A$-0.07
Shares Outstanding
164.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QRXPHARMA LTD (QRX)

Related News

No related news articles were found.

qrxpharma ltd (QRX) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd (QRX) Details

QRxPharma Limited, a specialty pharmaceutical company, develops and commercializes biopharmaceutical products primarily in Australia. The company’s pain management products include MOXDUO, which is an immediate-release oral capsule for the treatment of moderate to severe acute pain; Q8011, a controlled-release oral tablet that is a proprietary morphine/oxycodone formulation in Phase II clinical trials to provide analgesia in patients suffering from moderate to severe chronic pain; and Q8012, an intravenous dual opioid formulation of morphine and oxycodone, which has completed Phase II trial for acute moderate to severe hospital-based pain. It has a collaboration agreement with Aesica Formulation Development Limited for the promotion of its proprietary Stealth Beadlets abuse deterrence technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd (QRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$337.3K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$219.7K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$286.9K
Compensation as of Fiscal Year 2013.

qrxpharma ltd (QRX) Key Developments

QRxPharma Limited Announces Board Changes

QRxPharma Limited announced that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50 am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting. The Company also announced that directors Peter Campbell and Michael Quinn have tendered their resignations from the QRxPharma board.

QRxPharma Limited, Special/Extraordinary Shareholders Meeting, Jul 09, 2014

QRxPharma Limited, Special/Extraordinary Shareholders Meeting, Jul 09, 2014.

QRxPharma Limited Announces Executive Changes

QRxPharma Limited announced that Dr. John Holaday has stepped down as Managing Director and Chief Executive Officer. The company's Board of Directors has appointed Dr. Edward Rudnic to Chief Executive Officer with immediate effect. Dr. Rudnic has been company's Chief Operating Officer since early 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QRX:AU A$0.08 AUD -0.001

QRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QRX.
View Industry Companies
 

Industry Analysis

QRX

Industry Average

Valuation QRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD, please visit www.qrxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.